The alpha-7 nicotinic receptor, also known as the α7 receptor, is a type of nicotinic acetylcholine receptor implicated in long term memory, consisting entirely of α7 subunits. As with other nicotinic acetylcholine receptors, functional α7 receptors are pentameric [i.e., (α7)5 stoichiometry].
It is located in the brain, spleen, and lymphocytes of lymph nodes where activation yields post- and presynaptic excitation, mainly by increased Ca2+ permeability.
Recent work has demonstrated a potential role in reducing inflammatory neurotoxicity in stroke, myocardial infarction, sepsis, and alzheimers disease.
An α7 nicotinic agonist appears to have positive effects on neurocognition in persons with schizophrenia.
Both α4β2 and α7 nicotinic receptors appear to be critical for memory, working memory, learning, and attention.
α7-nicotinic receptors also appear to be involved in cancer progression. They have been shown to mediate cancer cell proliferation and metastasis. α7 receptors are also involved in angiogenic activity, and have anti-apoptotic effects.
(+)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzo[b]furan- 2-carboxamide: potent and highly subtype-selective
A-582941: partial agonist; activates ERK1/2 and CREB phosphorylation; enhances cognitive performance
AR-R17779: full agonist, nootropic
Amyloid beta: neurotoxic marker of Alzheimer's disease
TC-1698: subtype-selective; neuroprotective effects via activation of the JAK2/PI-3K cascade, neutralized by angiotensin II AT(2) receptor activation
TC-5619 - partial agonist, in development for treatment of schizophrenia
EVP-6124 - partial agonist with nootropic properties, in development for treatment of schizophrenia and Alzheimer's disease
GTS-21 - partial agonist, in development for treatment of schizophrenia and/or Alzheimer's disease
PHA-543,613 - selective and potent agonist with nootropic properties
PNU-282,987 - selective and potent agonist, but may cause long QT syndrome
PHA-709829: potent and subtype-selective; robust in vivo efficacy in a rat auditory sensory gating modelAnalogues: improved hERG safety profile over PNU-282,987
SSR-180,711: partial agonist
Tropisetron: subtype-selective partial agonist; 5-HT3 receptor antagonist
WAY-317,538 - selective potent full agonist with nootropic and neuroprotective properties
Anabasine
Acetylcholine
Nicotine
Choline
ICH-3: subtype-selective partial agonist;
At least two types of positive allosteric modulators (PAMs) can be distinguished.
PNU-120,596
NS-1738: marginal effects on α7 desensitization kinetics; modestly brain-penetrant
AVL-3288: unlike the above PAMs, AVL-3288 does not affect α7 desensitization kinetics, and is readily brain penetrant. Improves cognitive behavior in animal models In clinical development for cognitive deficits in schizophrenia.
A-867744
Ivermectin
Galantamine
Nefiracetam
It is found that anandamide and ethanol cause an additive inhibition on the function of α7-receptor by interacting with distinct regions of the receptor. Although ethanol inhibition of the α7-receptor is likely to involve the N-terminal region of the receptor, the site of action for anandamide is located in the transmembrane and carboxyl-terminal domains of the receptors.
Anandamide
α-Bungarotoxin
α-Conotoxin ArIB[V11L,V16D]: potent and highly subtype-selective; slowly reversible
Bupropion (very weakly)
Dehydronorketamine
Ethanol
Hydroxybupropion (very weakly)
Hydroxynorketamine
Ketamine
Kynurenic acid
Memantine
Lobeline
Methyllycaconitine
Norketamine
Quinolizidine (–)-1-epi-207I: α7 subtype preferring blocker
